Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma (Q43407740)

23 November 2017

title

Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma (English)

1 reference

23 November 2017

3

1 reference

23 November 2017

4

1 reference

23 November 2017

9

Carsten Bokemeyer

1 reference

23 November 2017

7

Holger Moch

1 reference

23 November 2017

Sarah Minner

1

1 reference

23 November 2017

Dorothea Rump

2

1 reference

23 November 2017

Eike Burandt

5

1 reference

23 November 2017

Luigi Terracciano

6

1 reference

23 November 2017

Waldemar Wilczak

8

1 reference

23 November 2017

Margit Fisch

10

1 reference

23 November 2017

Guido Sauter

11

1 reference

23 November 2017

Christian Eichelberg

12

1 reference

23 November 2017

language of work or name

English

0 references

publication date

1 March 2012

1 reference

23 November 2017

1 reference

23 November 2017

volume

118

1 reference

23 November 2017

issue

5

1 reference

23 November 2017

page(s)

1268-1275

1 reference

Untangling the ErbB signalling network

23 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

ERBB receptors and cancer: the complexity of targeted inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

EGF-r gene copy number changes in renal cell carcinoma detected by fluorescence in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

Role of transforming growth factor-alpha in von Hippel--Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

Chromosomal aberrations and gene expression profiles in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

TP53, EGFR, and KRAS mutations in relation to VHL inactivation and lifestyle risk factors in renal-cell carcinoma from central and eastern Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

Amplification of epidermal growth factor receptor gene in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

7 January 2021

Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

7 January 2021

Proliferating cell nuclear antigen and epidermal growth factor receptor (EGFr) status in renal cell carcinoma patients with polysomy of chromosome 7

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

7 January 2021

Amplification and overexpression of the epidermal growth factor receptor gene in human renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

7 January 2021

Epidermal growth factor receptor gene expression and binding capacity in renal cell carcinoma, in relation to tumor stage, grade and DNA ploidy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

7 January 2021

Epidermal growth factor family and renal cell carcinoma: expression and prognostic impact

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

7 January 2021

Prognostic significance of morphologic parameters in renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

7 January 2021

Phosphorylation, But Not Overexpression, of Epidermal Growth Factor Receptor Is Associated With Poor Prognosis of Non-Small Cell Lung Cancer Patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

7 January 2021

Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

7 January 2021

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26436

7 January 2021

Identifiers

DOI

10.1002/CNCR.26436

1 reference

23 November 2017

1 reference